GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

The drugmaker had earlier reported positive efficacy results from DREAMM-7, another phase III head-to-head trial evaluating belantamab mafodotin in combination with bortezomib and dexamethasone ...

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...

Piper Sandler analyst Michael S. Lavery upgraded Campbell Soup Company (NASDAQ:CPB) to Overweight from Neutral, raising the ...

The Fresh Market’s most recent store opening in the Chicago neighborhood of Lincoln Park took the place of a Dom’s Kitchen ...